Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Acute 3Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Extensive Stage Lung Small Cell Cancer 1Carcinoma, Pancreatic Ductal 1Carcinoma 1

Interventions

Tacrolimus 2Specimen Handling 2Lymphatic Irradiation 2Biopsy 2venetoclax 1selinexor 1olutasidenib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Thiotepa 1Sirolimus 1Receptors, Antigen, T-Cell 1Quality of Life 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Maintenance 1Levofloxacin 1Idarubicin 1Fibroblast Growth Factor 7 1Electrocardiography 1Cytarabine 1Clinical Laboratory Techniques 1Busulfan 1Bone Marrow Examination 1Blood Specimen Collection 1Azacitidine 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Myelodysplastic Syndromes × selinexor × Clear all
NCT06900088 2025-03-28

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
20 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡